What is NSPR's market cap?

$36.58M, based on the Nov 4 close of $0.78.

Does InspireMD pay a dividend?

No regular cash dividend has been paid in the last year.

How much of NSPR is sold short?

80.9K shares, 0.2% of float, as of Oct 15, 2026.

What sector is NSPR in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · NSPRHealthcareSurgical Instruments

InspireMD, Inc. (NSPR)

$0.7810+18.71%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$0.78▼ 63.25% in range

Nov 4, 2025Low $0.44 · High $2.15Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

InspireMD closed at $0.78 on Nov 4, up 18.71%, 65.9% below its 52-week closing high. Volume of 511.6K shares was 1.68× its 20-day average (above normal).

Split-adjusted performance: +48.7% over one month, -32.7% over six months, -65.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.77M, down 0.4% from a year earlier, with a net margin of -808.8%.

Short interest was 80.9K shares at the Oct 15 settlement, up 260.1% from the prior report (0.2% of float, 1.0 days to cover).

Market cap$36.6M46.8M shares

Revenue · quarter$1.8M−0.4% YoY

Diluted EPS$-0.17—

P/E · TTM—P/S 3.4×

Net margin-808.8%Gross -43.7%

Dividend yieldNone

52-week range0.44 – 2.29−65.9% from high

Volume511.6K1.68× 20-day avg

Volatility · 60d95.9%Annualised

Short % of float0.2%1.0 days to cover

Net cash$30.4MCash $30.4M

Next earnings—Not scheduled

Split-adjusted performance

1W +66.9%1M +48.7%3M +8.1%6M −32.7%YTD −56.1%1Y −65.9%3Y −73.0%5Y −80.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum28

Revenue growth21

Net margin7

Value (low P/E)—

Size28

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short80.9K+260.1% vs prior

Days to cover1.0Settled Oct 15

% of float0.2%

Short vol. 10d54.1%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
NSPRInspireMD	$0.7810	+18.71%	−32.7%	−0.4%	−808.8%	—	$36.6M
TELATELA Bio	$0.8378	+4.46%	−15.4%	−4.5%	−58.4%	—	$37.8M	Compare
NEPHNephros	$3.25	+0.31%	+0.9%	+36.2%	19.9%	20.3	$35.3M	Compare
XTNTXtant Medical Holdings	$0.2960	+6.47%	−48.7%	−35.0%	−40.9%	—	$41.5M	Compare
CVRXCVRx	$1.58	+14.49%	−77.7%	+15.6%	−89.4%	—	$42.1M	Compare
DRIODarioHealth	$2.97	−1.00%	−62.8%	−3.6%	−153.1%	0.0	$29.1M	Compare
MDAISpectral AI	$1.53	+2.00%	−31.1%	−30.4%	−118.5%	—	$49.2M	Compare
SNWVSANUWAVE Health	$5.73	−3.37%	−64.0%	−3.1%	−7.0%	3.4	$49.3M	Compare
DXRDaxor	$8.91	+2.44%	−12.1%	+2.3%	−403.2%	—	$52.0M	Compare

News about InspireMD

All news →

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 MillionGlobeNewswire Inc. · Sep 21, 2026▲ Positive InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR ProceduresGlobeNewswire Inc. · Jun 8, 2026▲ Positive

Quick answers

What does InspireMD do?: InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease.
What is NSPR's market cap?: $36.58M, based on the Nov 4 close of $0.78.
Does InspireMD pay a dividend?: No regular cash dividend has been paid in the last year.
How much of NSPR is sold short?: 80.9K shares, 0.2% of float, as of Oct 15, 2026.
What sector is NSPR in?: Healthcare, in the Surgical Instruments industry.

About InspireMD

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

HQ: Miami, FL127 employeesListed Aug 22, 1997inspiremd.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology